“RIP Ivermectin”


“RIP Ivermectin”

Former health minister Dzulkefly Ahmad has applauded the findings of a health ministry research on Ivermectin, which indicated that the controversial medicine, which is distributed on the black market, did not reduce the risk of severe disease among Covid-19 patients in categories 4 and 5.

Dzulkefly said that the I-tech research was carried out on the premise of “evidence-based medicine" and was based on data gathered from randomised clinical trials undertaken by the ministry and that it “corroborated well and is in sync with other (international) findings."

“Definitive hypothesis testing trials like TOGETHER (an Ivermectin trial in three countries) and the I-tech study are crucial in deciding whether a treatment modality will be included in national or international treatment guidelines,” he said in a statement with FMT.

“Not poorly conducted, underpowered hypothesis-generating trials which have created confusion to some practitioners and the public alike.”


Dzulkefly, the former Pakatan Harapan administration’s health minister, also dismissed claims by a doctor whose clinic was raided by authorities for giving Ivermectin to his patients that the ministry’s research could not reach any conclusions on its effectiveness for preventive and early treatment.

Dr. Amir Farid Isahak told FMT last night that the research only included hospitalised patients and that it cannot draw any conclusions about the effectiveness of Ivermectin as preventative and early treatment for Category 1 and mild Category 2 Covid-19 cases.

He also said that the trial had no effect on “our perspective" on Ivermectin for prophylactic and early treatment.

In response to Amir’s attitude, Dzulkefly said that studies were developed and carried out to answer a particular research question with a specified primary hypothesis, referring to this as the “basics of a clinical trial."

“The I-tech study is designed for a specific research question,” he added.

“If, at all, you find a positive finding in a secondary objective or hypothesis, you must undertake another trial with a specific primary objective and hypothesis.”

Dr. Noor Hisham Abdullah, director-general of health, said yesterday that based on the study’s findings, the ministry does not recommend that Ivermectin be included in current Covid-19 treatment guidelines since it did not reduce the risk of severe illness from Covid-19.

He further cautioned doctors not to promote and sell Ivermectin for the treatment of Covid-19 “until there is more solid scientific evidence”.

The research included 500 Covid-19 patients over the age of 50 who had at least one comorbidity and had been admitted to hospital after being classified as Category 2 (symptomatic without pneumonia) or Category 3 (symptomatic with pneumonia).

It was intended to determine if administering Ivermectin to such individuals during the first week of Covid-19 symptoms would prevent them from progressing to Category 4 (pneumonia requiring oxygen treatment) and Category 5 (critical and requiring assisted ventilation).

17.3 percent of those who received conventional treatment advanced to Category 4 and 5, compared to 21.2 percent of those who received Ivermectin.

Those in the standard care group advanced to Category 4 and 5 in 2.9 days, whereas those in the Ivermectin group advanced to Category 4 and 5 in three days.

source - the guardian

Meanwhile, the Ivermectin group had three times the number of adverse events – predominantly diarrhoea – as that of the normal care group.

In response to the test results, Malaysian Pharmacists Society president Amrahi Buang said that the data “finally show" that Ivermectin is not recommended for the treatment of Covid-19.

He said that the results were consistent with comparable studies in Brazil and Argentina and urged the “pro Ivermectin group" to accept them.

“If they want to do a different study, they are most welcome and must follow proper protocol,” he said.

“We hope the public stops using Ivermectin immediately.”

Ivermectin is mostly used in veterinary medicine in Malaysia, and there have been numerous debates concerning its application to treat Covid-19 in humans. A number of opposition MPs pressed the administration to look into the matter in July.

source - the edge markets

Ivermectin was a popular subject on Twitter yesterday night, with former health deputy director-general Dr Christopher Lee among those applauding doctors and others participating in the studies, which took place throughout government hospitals and at the Malaysia Agro Exposition Park Serdang’s low-risk quarantine and treatment centre.

“Well-designed and robust clinical research must always drive our clinical practice,” he said.

Dr Rafidah Abdullah, a consultant physician and nephrologist at Hospital Putrajaya, was among the most vocal opponents of Ivermectin’s use, who provided a clear picture of the dangers of taking the medication to prevent or treat Covid-19 in August.

“I’m always seeing complications from Ivermectin. I’ve given up,” she tweeted.

“A patient who recovered from Covid-19 also wanted to take Ivermectin, and now (the patient’s) liver functions have become problematic. Yellow – jaundice.”

She was more succinct yesterday, when she retweeted a health ministry infographic outlining the findings of the I-tech research.

“RIP Ivermectin.”

Previous Post

What To Do After You Overeat

Next Post

Public Urged To Stop Using Ivermectin Illegally To Treat Covid

Related Posts